FR15C0081I1 - OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST - Google Patents

OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST

Info

Publication number
FR15C0081I1
FR15C0081I1 FR15C0081C FR15C0081I1 FR 15C0081 I1 FR15C0081 I1 FR 15C0081I1 FR 15C0081 C FR15C0081 C FR 15C0081C FR 15C0081 I1 FR15C0081 I1 FR 15C0081I1
Authority
FR
France
Prior art keywords
hpv
yeast
optimized expression
optimized
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of FR15C0081I1 publication Critical patent/FR15C0081I1/en
Application granted granted Critical
Publication of FR15C0081I2 publication Critical patent/FR15C0081I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR15C0081C 2003-11-12 2015-12-04 OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST Active FR15C0081I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51921103P 2003-11-12 2003-11-12
PCT/US2004/037372 WO2005047315A2 (en) 2003-11-12 2004-11-10 Optimized expression of hpv 58 l1 in yeast

Publications (2)

Publication Number Publication Date
FR15C0081I1 true FR15C0081I1 (en) 2016-08-01
FR15C0081I2 FR15C0081I2 (en) 2016-11-25

Family

ID=34590374

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0081C Active FR15C0081I2 (en) 2003-11-12 2015-12-04 OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST

Country Status (32)

Country Link
US (2) US7498036B2 (en)
EP (1) EP1687329B8 (en)
JP (2) JP4912885B2 (en)
KR (1) KR101170654B1 (en)
CN (1) CN1942583B (en)
AR (1) AR046835A1 (en)
AT (1) ATE452977T1 (en)
AU (1) AU2004290032B2 (en)
BE (1) BE2015C070I2 (en)
BR (1) BRPI0416393B1 (en)
CA (1) CA2543928C (en)
CY (2) CY1113875T1 (en)
DE (1) DE602004024821D1 (en)
DK (1) DK1687329T3 (en)
ES (1) ES2340287T3 (en)
FR (1) FR15C0081I2 (en)
HU (1) HUS1500064I1 (en)
IL (1) IL175353A (en)
IS (1) IS2741B (en)
LT (1) LTC1687329I2 (en)
LU (1) LU92901I2 (en)
MY (1) MY139500A (en)
NL (1) NL300775I1 (en)
NO (3) NO340633B1 (en)
NZ (1) NZ546697A (en)
PL (1) PL1687329T3 (en)
PT (1) PT1687329E (en)
RU (1) RU2370538C2 (en)
SI (1) SI1687329T1 (en)
TW (1) TWI332988B (en)
WO (1) WO2005047315A2 (en)
ZA (1) ZA200603106B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US8206950B2 (en) 2003-06-09 2012-06-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine and method of making them
CA2560487C (en) * 2004-03-24 2013-01-29 Merck & Co., Inc. Optimized expression of hpv 52 l1 in yeast
US20070243587A1 (en) * 2006-04-14 2007-10-18 Healthbanks Biotech Co., Ltd. Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (en) * 2006-09-18 2013-01-02 中国医学科学院基础医学研究所 Human papilloma virus 16 type coat protein virus-like particles, preparation method and use thereof
WO2008112125A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
US9428555B2 (en) 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
CN101343315B (en) * 2007-05-29 2012-06-13 厦门大学 Shorten human papilloma virus 6 type L1 protein
CN101113417B (en) * 2007-06-22 2011-04-27 山东大学 Establishment of HPV gene yeast external translating system
CN101200696B (en) * 2007-11-14 2011-07-20 山东大学 Yeast proliferation model of human papilloma virus as well as constructing method and uses
EP2223933B1 (en) * 2007-11-23 2016-01-27 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein l1 of human papilloma viruses
KR20090073987A (en) * 2007-12-31 2009-07-03 정운원 Primer, Probe, DNA Chip containg the Same and Method for Detecting Human Papillomavirus and Detection Kit Thereof
JP5726727B2 (en) * 2008-05-26 2015-06-03 カディラ・ヘルスケア・リミテッド Measles-human papilloma combination vaccine
US9335868B2 (en) * 2008-07-31 2016-05-10 Apple Inc. Capacitive sensor behind black mask
JP6153866B2 (en) 2010-05-25 2017-06-28 キアゲン ガイサーズバーグ アイエヌシー． Rapid hybrid capture assay and associated strategically cleaved probe
CN101857870B (en) * 2010-06-12 2012-09-05 上海泽润生物科技有限公司 HPV58 L1 gene, vector, strain and expression method
BR112013000996B1 (en) * 2010-07-16 2021-08-10 Xiamen Innovax Biotech Co., Ltd. HPV58 TRUNCATE L1 PROTEIN, ISOLATED NUCLEIC ACID, VECTOR, HOST CELL, HPV58 VIRAL TYPE Particle, COMPOSITION, PHARMACEUTICAL COMPOSITION OR VACCINE, METHOD FOR OBTAINING A TRUNCATED HPV58 L1 PROTEIN, METHOD TO PREPARE A TIPO58 TI-PARTI VACCINE, AND USE OF TRUNCATE L1 HPV58 PROTEIN
CN102154325B (en) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 Vaccine against human papillomavirus (HPV) as well as preparation method and application thereof
CA2839427C (en) * 2011-06-15 2016-09-27 Chung-Ang University Industry-Academic Cooperation Foundation Method for enhancing the production yield of human papillomavirus l1 protein
CN108624614A (en) * 2012-03-28 2018-10-09 北京安百胜生物科技有限公司 The method for generating HPV11 L1 albumen with expressed by Hansenula yeast system
JP6423987B2 (en) * 2012-06-07 2018-11-14 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Controlled gene expression method
CN103992395B (en) * 2013-02-18 2018-07-27 北京康乐卫士生物技术股份有限公司 Recombinate the VLP vaccines and preparation method thereof of HPV-58 types L1
CN104120088B (en) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 The method for generating HPV58 L1 albumen with expressed by Hansenula yeast system
CN110592133A (en) * 2013-05-17 2019-12-20 北京安百胜生物科技有限公司 Method for producing HPV31L1 protein by using hansenula polymorpha expression system
CN104164373B (en) * 2013-05-17 2019-04-02 北京安百胜生物科技有限公司 The method for generating HPV68L1 albumen with expressed by Hansenula yeast system
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
AU2015313756A1 (en) * 2014-09-11 2017-03-09 Cadila Healthcare Limited Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN106148359A (en) * 2015-03-30 2016-11-23 上海泽润生物科技有限公司 Recombinant human papilloma virus 33 subtype protein is expressed
CN104878022A (en) * 2015-04-27 2015-09-02 段青姣 Nucleotide sequence for coding HPV58L1 and HPV52L1 proteins and application thereof
CN106831961B (en) * 2015-12-04 2019-11-05 厦门大学 A kind of mutant of human papillomavirus type 58 L1 albumen
MX2022009964A (en) 2020-02-14 2022-09-19 Merck Sharp & Dohme Llc Hpv vaccine.
CN113073105B (en) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 Polynucleotide sequence for expressing HPV56L1, expression vector, host cell and application thereof
CN113549634B (en) * 2021-06-07 2023-03-31 郑州大学 Gene for coding soluble HPV58L1 protein and construction and application of recombinant plasmid thereof
TW202313658A (en) 2021-08-06 2023-04-01 美商默沙東有限責任公司 Hpv vaccine
MX2024002144A (en) 2021-08-19 2024-04-23 Merck Sharp & Dohme Llc Thermostable lipid nanoparticle and methods of use thereof.
CN117054647A (en) * 2023-07-17 2023-11-14 广东省一鼎生物技术有限公司 Kit for detecting HPV IgG antibody and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117591A0 (en) 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
US5821087A (en) 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
ATE342916T1 (en) 1997-02-07 2006-11-15 Merck & Co Inc SYNTHETIC HIV GAG GENES
JP4434479B2 (en) 1997-07-09 2010-03-17 ザ・ユニバーシティ・オブ・クイーンズランド Nucleic acid sequences and methods for selectively expressing proteins in target cells and tissues
PL347472A1 (en) * 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
DE69933875T2 (en) 1998-08-14 2007-05-31 Merck & Co., Inc. PROTEIN ADMINISTRATION SYSTEM USING SIMILAR PARTICLES TO HUMAN PAPILLOMA VIRUS.
SE514982C2 (en) * 1999-09-30 2001-05-28 Active Biotech Ab Carrier containing a major capsid protein L1 from human papillomavirus and its use
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
DE60124918T2 (en) 2000-07-21 2007-08-02 Glaxo Group Ltd., Greenford CODON-OPTIMIZED PAPILLOMA VIRUS SEQUENCES
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
BRPI0408639B8 (en) 2003-03-24 2021-05-25 Merck Sharp & Dohme nucleic acid molecule, vector, yeast host cell, and method for producing hpv31 virus-like particles
MY140664A (en) 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
CA2543928C (en) 2011-04-05
RU2370538C2 (en) 2009-10-20
LTC1687329I2 (en) 2017-05-10
TW200519203A (en) 2005-06-16
EP1687329A2 (en) 2006-08-09
NO340633B1 (en) 2017-05-15
NO2017058I1 (en) 2017-11-10
US7976848B2 (en) 2011-07-12
EP1687329B1 (en) 2009-12-23
TWI332988B (en) 2010-11-11
PL1687329T3 (en) 2010-06-30
DK1687329T3 (en) 2010-04-12
JP4912885B2 (en) 2012-04-11
BRPI0416393B1 (en) 2021-06-29
WO2005047315A3 (en) 2006-09-28
KR20060122852A (en) 2006-11-30
NL300775I2 (en) 2015-12-29
US7498036B2 (en) 2009-03-03
HUS1500064I1 (en) 2016-02-29
KR101170654B1 (en) 2012-08-03
JP2008500019A (en) 2008-01-10
AU2004290032B2 (en) 2009-02-05
CY2015051I1 (en) 2016-06-22
IS8425A (en) 2006-04-21
FR15C0081I2 (en) 2016-11-25
IS2741B (en) 2011-06-15
CN1942583B (en) 2010-10-27
ES2340287T3 (en) 2010-06-01
US20070036824A1 (en) 2007-02-15
NL300775I1 (en) 2015-12-29
LU92901I2 (en) 2016-03-08
AR046835A1 (en) 2005-12-28
NZ546697A (en) 2009-05-31
ZA200603106B (en) 2007-09-26
AU2004290032A1 (en) 2005-05-26
JP5616879B2 (en) 2014-10-29
NO20062674L (en) 2006-06-09
WO2005047315A2 (en) 2005-05-26
US20100272749A1 (en) 2010-10-28
EP1687329B8 (en) 2010-03-17
JP2012095652A (en) 2012-05-24
CA2543928A1 (en) 2005-05-26
DE602004024821D1 (en) 2010-02-04
CY2015051I2 (en) 2016-06-22
CN1942583A (en) 2007-04-04
IL175353A (en) 2010-11-30
ATE452977T1 (en) 2010-01-15
IL175353A0 (en) 2006-09-05
BRPI0416393A (en) 2007-04-03
PT1687329E (en) 2010-02-26
RU2006120402A (en) 2007-12-27
CY1113875T1 (en) 2016-06-22
NO2022052I1 (en) 2022-11-30
MY139500A (en) 2009-10-30
SI1687329T1 (en) 2010-03-31
BE2015C070I2 (en) 2023-12-18

Similar Documents

Publication Publication Date Title
FR15C0081I2 (en) OPTIMIZED EXPRESSION OF HPV 58 L1 IN YEAST
FR15C0083I2 (en) OPTIMIZED EXPRESSION OF HPV45 L1 IN YEAST
FR15C0085I2 (en) OPTIMIZED EXPRESSION OF HPV 52 L1 IN A YEAST
DE60317699D1 (en) FERMENTATION PROCESSES AND COMPOSITIONS
DE60318819D1 (en) HITZESTABILE MUTANTS OF STRENGTH BIOSYNTHESEENZYMEN
FR2842104B1 (en) GENES INVOLVED IN EARLY CANITIS
FR2842105B1 (en) LOCATION OF THE GENES INVOLVED IN THE EARLY CANITIE
ES1054384Y (en) IMPROVEMENTS IN THE CONSTRUCTION STRUCTURE OF TRICYCLES
ITMC20030128A1 (en) POSITIVE CONVERSION OF THE NEGATIVE THRUST THROUGH